Answers are grounded in this paper and cite their sources.
The results of this study indicate that combination therapies based on bortezomib and bevacizumab might offer an increased benefit when the two agents are used in combination. These drugs have a complementary mechanism of action and therefore can be used together to treat TMZ-resistant malignant gliomas.
No takes yet. Share an insight, caveat, or question.
Bota et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: